Table 3:
Psychiatric Characteristics of the Entire Sample and Split Based on ASD Diagnosis (mean±std, unless noted otherwise)
| Entire Sample n=186 |
No-ASD n=156 |
ASD n=30 |
Statistic | p-value | |
|---|---|---|---|---|---|
| ADHD, n (%) | 170 (91) | 143 (92) | 27 (90) | χ2= 0.09 | 0.77 |
| DBD, n (%) | 171 (92) | 147 (94) | 24 (80) | χ2= 6.87 | 0.0088 |
| Depressive Disorder, n (%) | 9 (5) | 9 (6) | 0 | Fisher’s Exact | 0.36 |
| Anxiety Disorder, n (%) | 60 (32) | 56 (36) | 4 (13) | χ2= 5.86 | 0.016 |
| Tic Disorder, n (%) | 39 (21) | 34 (22) | 5 (17) | χ2= 0.40 | 0.53 |
| Pharmacotherapy | |||||
| MPH Use, n (%) | 133 (72) | 116 (74) | 17 (57) | χ2= 0.90 | 0.049 |
| MPH Tx Duration, yrs¶ | 4.1±2.8 | 5.9±0.2 | 4.8±0.5 | Wilcoxon = 2685 | 0.66 |
| SSRI, n (%) | 88 (47) | 64 (41) | 24 (80) | χ2= 15.33 | <0.0001 |
| SSRI Tx Duration, yrs¶ | 2.0±1.8 | 1.2±0.1 | 2.5±0.3 | Wilcoxon = 3905.5 | <0.0001 |
| Risperidone Tx Duration, yrs¶ | 2.8±2.0 | 2.9±0.2 | 3.5±0.4 | Wilcoxon = 3186.5 | 0.16 |
ADHD: attention deficit hyperactivity disorder, DBD: disruptive behavior disorder, ASD: Autism Spectrum Disorder, MPH Tx: treatment with psychostimulants, SSRI Tx: treatment with selective serotonin reuptake inhibitors.
¶
: Results for the two clinical groups are reported as least squares means and standard error, given that the analyses are adjusted for age.
Significant results (p<0.05) are bolded.